Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions.

Breast cancers often contain different clones of tumor cells. Attention to the cellular properties of breast cancer metastases may identify characteristics in primary tumors that are associated with metastasis. Such characteristics could include DNA content, cell proliferation, abnormal oncogene expression, or relative cell population (clonal dominance). We examined DNA ploidy (image analysis), proliferation index (proliferating cell nuclear antigen-1 immunostaining), and expression of Her-2/neu oncoprotein in 17 invasive breast cancer samples (36 primary tumor samples) and 82 corresponding regional metastases. In all samples the primary tumor was multiclonal (usually biclonal) by DNA ploidy analysis. In approximately 90% of metastatic DNA clones (30 of 34) the corresponding clone was identified in a primary tumor sample representing 25% or more of the tumor cell population (significant clone). A majority DNA clone (> or = of tumor cell population) existed in 60% (21 of 36) of primary tumor samples and in 70% (60 of 82) of metastases (30% diploid v 70% nondiploid in both groups). In approximately 50% of metastases (37 of 82) an unexpected majority clone was identified (not a majority in any primary tumor sample) and the ratio of diploid to nondiploid clones also was 30% to 70%. However, in 80% of majority metastatic clones (46 of 60) that clone was a significant primary tumor clone. Proliferation index was quite variable in primary tumor samples and in corresponding metastases. Overexpression of Her-2/neu oncoprotein in the primary tumor of seven of 10 patients also was identified in all corresponding metastases in five of seven patients and in some metastases in two of seven patients. The metastases in three Her-2/neu-negative patients were all negative. We conclude that (1) DNA clones are stable after metastasis, (2) clonal majorities in metastases reflect clones identified in primary tumors, (3) different metastatic clones from an individual tumor can establish clonal majorities, (4) neither diploid nor aneuploid cells have a metastatic advantage in breast cancer, (5) proliferation indices are heterogeneous, and (6) overexpression of Her-2/neu is usually consistent between primary tumors and corresponding metastases.

[1]  J. Izbicki,et al.  Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. , 1993, Journal of the National Cancer Institute.

[2]  C. Cornelisse,et al.  Flow cytometric analysis of DNA stemline heterogeneity in primary and metastatic breast cancer. , 1991, Cytometry.

[3]  A. Campbell,et al.  Aneuploid subpopulations in tumour-invaded lymph nodes from breast cancer patients. , 1992, European journal of cancer.

[4]  G. Fleuren,et al.  High levels of DNA index heterogeneity in advanced breast carcinomas. Evidence for DNA ploidy differences between lymphatic and hematogenous metastases , 1993, Cancer.

[5]  J. Bacus,et al.  HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer. , 1990, Archives of pathology & laboratory medicine.

[6]  Y. Monden,et al.  Comparison of estrogen receptor and epidermal growth factor receptor content of primary and involved nodes in human breast cancer , 1991, Cancer.

[7]  H. Frierson Ploidy Analysis and S‐Phase Fraction Determination by Flow Cytometry of Invasive Adenocarcinomas of the Breast , 1991, The American journal of surgical pathology.

[8]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[9]  D. Visscher,et al.  Prognostic significance of morphological parameters and flow cytometric DNA analysis in carcinoma of the breast. , 1990, Pathology annual.

[10]  R. Camplejohn,et al.  DNA index, S-phase fraction, histological grade and prognosis in breast cancer. , 1990, British Journal of Cancer.

[11]  I. Ellis,et al.  An observation of DNA ploidy, histological grade, and immunoreactivity for tumour‐related antigens in primary and metastatic breast carcinoma , 1989, The Journal of pathology.

[12]  P. Gimotty,et al.  A retrospective analysis of breast cancer based on outcome differences. , 1991, Human pathology.

[13]  P. Galand,et al.  Cyclin/PCNA immunostaining as an alternative to tritiated thymidine pulse labelling for marking S phase cells in paraffin sections from animal and human tissues , 1989, Cell and tissue kinetics.

[14]  R. Kerbel,et al.  Cytogenetic heterogeneity of genetically marked and metastatically competent "dominant" tumor cell clones. , 1991, Cancer Genetics and Cytogenetics.

[15]  A. Cornaglia,et al.  Tissue fixation for immunohistochemical detection of proliferating cell nuclear antigen with PC10 monoclonal antibody. , 1994, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

[16]  P. Silcocks,et al.  Delay in fixation does not affect the immunoreactivity of proliferating cell nuclear antigen (PCNA) , 1992, The Journal of pathology.

[17]  R. Gelber,et al.  Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  R. Kerbel,et al.  Genetic evidence for progressive selection and overgrowth of primary tumors by metastatic cell subpopulations. , 1988, Cancer research.

[19]  J. Fuhr,et al.  Flow cytometric determination of breast tumor heterogeneity , 1991, Cancer.

[20]  G. Mazzini,et al.  Cell cycle‐related proteins: a flow cytofluorometric study in human tumors , 1988, Biology of the cell.

[21]  F. Miller,et al.  Dominance of a tumor subpopulation line in mixed heterogeneous mouse mammary tumors. , 1988, Cancer research.

[22]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[23]  T. Singleton,et al.  Stability of HER-2/neu expression over time and at multiple metastatic sites. , 1993, Journal of the National Cancer Institute.

[24]  R. Kerbel,et al.  Dominance of metastatically competent cells in primary murine breast neoplasms is necessary for distant metastatic spread , 1991, International Journal of Cancer.

[25]  H. Wolf,et al.  Detection of proliferating cell nuclear antigen in diagnostic histopathology. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[26]  R. Kerbel Growth dominance of the metastatic cancer cell: cellular and molecular aspects. , 1990, Advances in cancer research.

[27]  G. Fleuren,et al.  Evidence for limited molecular genetic heterogeneity as defined by allelotyping and clonal analysis in nine metastatic breast carcinomas. , 1993, Cancer research.

[28]  P. V. van Diest,et al.  Quantitation of HER-2/neu oncoprotein overexpression in invasive breast cancer by image analysis: a study comparing fresh and paraffin-embedded material. , 1991, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[29]  D. Lane,et al.  Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some, neoplasms , 1990, The Journal of pathology.

[30]  J. H. Dierendonck,et al.  Cell-cycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies. Comparison with BrdUrd labeling and Ki-67 staining. , 1991, The American journal of pathology.

[31]  L. Case,et al.  The use of flow cytometry for the prognosis of stage II adjuvant treated breast cancer patients , 1990, Cancer.

[32]  L. Ottestad,et al.  The c-erbB-2 protein in primary and metastatic breast carcinomas. , 1991, Ultrastructural pathology.

[33]  I. Fidler,et al.  Changes in clonal composition during in vivo growth of mixed subpopulations derived from the murine K-1735 melanoma. , 1990, Anticancer research.

[34]  B. Ljung,et al.  Heterogeneity for allelic loss in human breast cancer. , 1992, Journal of the National Cancer Institute.

[35]  P. V. van Diest,et al.  Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[36]  M G Daidone,et al.  Proliferative activity of primary breast cancer and of synchronous lymph node metastases evaluated by [3H]‐thymidine labelling index , 1990, Cell and tissue kinetics.

[37]  J. Meyer,et al.  Regional heterogeneity in breast carcinoma: Thymidine labelling index, steroid hormone receptors, dna ploidy , 1991, International journal of cancer.

[38]  P. Frost,et al.  Genotypic and phenotypic evidence of clonal interactions in murine tumor cells. , 1989, Journal of the National Cancer Institute.

[39]  H. Joensuu,et al.  The prognostic significance of nuclear DNA content in invasive breast cancer--a study with long-term follow-up. , 1989, British Journal of Cancer.

[40]  G. Heppner Tumor cell societies. , 1989, Journal of the National Cancer Institute.

[41]  Rochelle L. Garcia,et al.  Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis. , 1989, The American journal of pathology.

[42]  M. J. van de Vijver,et al.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.

[43]  G. Auer,et al.  Comparison of DNA distributions in primary human breast cancers and their metastases. , 1980, European journal of cancer.

[44]  D. Schaid,et al.  DNA ploidy and percent S-phase as prognostic factors in node-positive breast cancer: results from patients enrolled in two prospective randomized trials. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.